In:
Journal of Translational Medicine, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2023-09-06)
Kurzfassung:
Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) has emerged as a novel immunotherapy candidate, which deserves a comprehensive investigation in lung adenocarcinoma (LUAD). Methods Multiplex fluorescence‐based immunohistochemistry was conducted to assess Siglec-15 expression and tumor-infiltrating immune cells in LUAD from Tianjin cohort, with validation cohorts Xinchao 04 and 07. Results This study revealed that Siglec-15 was positively correlated with CD8 + T cells and tumor-associated macrophages (TAMs) infiltration, but CD8 + T cells were mostly infiltrated in the stroma area, not in the tumor area. Spatially, fewer CD8 + T cells surrounded Siglec-15 + tumor cells in PD-L1 − cells, and more TAMs surrounded Siglec-15 + tumor cells in PD-L1 −/+ cells. Siglec-15 + TAMs infiltrated with more CD8 + T cells, and were closer to CD8 + T cells than Siglec-15 − TAMs and Siglec-15 + tumor cells. Siglec-15 + TAMs infiltrated with more Tregs and were closer to Tregs than Siglec-15 + tumor cells. Siglec-15 + tumor cells or TAMs reversed CD8 + T cells prognosis value, and enhanced the prognosis value of Tregs and TAMs. The immunotyping based on Siglec-15 and CD8A / CD8 + T cells revealed that patients with high CD8A and Siglec-15 expression exhibited immune activation. Patients with low CD8A expression / CD8 + T cells infiltration and Siglec-15 overexpression were related to the activation of immunosuppressive signature and metabolism-related pathway, and infiltrated with more TAMs. Conclusions We revealed the distinct characteristics between Siglec-15 + tumor cells and TAMs in relation to CD8 + T cells, and a unique relationship between Siglec-15 and immunosuppressive TIME in LUAD, which may provide potential value for anti-Siglec-15 therapy.
Materialart:
Online-Ressource
ISSN:
1479-5876
DOI:
10.1186/s12967-023-04489-6
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2023
ZDB Id:
2118570-0
